Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 4/20 | 0.42 |
| ▸ | ANPEP | P15144 | 3/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | GABRP | O00591 | 2/20 | 0.39 |
| ▸ | GABRD | O14764 | 2/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.39 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.39 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.39 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28799207 | 0.97 | SLC22A6 (0.47) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL6734053 | 0.97 | SLC22A6 (0.47) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7372643 | 0.97 | SLC22A6 (0.47) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| Acetic Acid SCHEMBL2595033 | 0.91 | SLC22A6 (0.43) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL10142141 | 0.88 | SLC22A6 (0.41) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL288572 | 0.88 | SLC22A6 (0.41) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL19405330 | 0.88 | SLC22A6 (0.41) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL18265152 | 0.86 | TDP1 (0.43) | SLC22A6GABRR1LMNATDP1SMN1; SMN2 | |
| SCHEMBL4335769 | 0.84 | — | — | |
| SCHEMBL4340953 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 914 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4737477-A2 | HEPCIDIN MIMETICS FOR TREATMENT OF HEREDITARY HEMOCHROMATOSIS | Protagonist Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4706671-A2 | CONJUGATED HEPCIDIN MIMETICS | Protagonist Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| US-20250360187-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | PROTAGONIST THERAPEUTICS, INC. (US) | 2025-11-27 | — | — | US | claimed |
| WO-2025217074-A1 | KISSPEPTIN RECEPTOR (KISS1R) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | PROTAGONIST THERAPEUTICS, INC. | 2025-09-04 | — | — | US | claimed |
| US-12378328-B2 | Biohybrid peptidoglycan oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2025-08-05 | — | — | US | claimed |
| CN-117383660-B | Graphene-based composite electrode and preparation method and application thereof | 南京理工大学 | 2025-05-23 | — | — | CN | claimed |
| CN-119930947-A | Alkali-soluble thickener, and preparation method and application thereof | 苏州博纳化学科技有限公司 | 2025-05-06 | — | — | CN | claimed |
| WO-2025044828-A9 | USE AND COMPOSITION OF POSTBIOTIC OF LACTOBACILLUS PARACASEI ET-22 | 内蒙古伊利实业集团股份有限公司 | 2025-04-03 | — | — | WO | claimed |
| CN-119708088-A | Disaccharide-acylhydrazone or disaccharide-hydrazide linker, sugar engineering antibody based on same, sugar chain fixed-point antibody-drug conjugate and application | 上海糖岭生物医药有限责任公司 | 2025-03-28 | — | — | CN | claimed |
| EP-1276732-A1 | AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION\ | Dompé S.P.A. (IT) | 2003-01-22 | — | — | EP | claimed |
| EP-1255726-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8 INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.P.A. (IT) | 2002-11-13 | — | — | EP | claimed |
| WO-2001079189-A2 | 'AMIDES OF R-2-(AMINOARYL)-PROPIONIC ACIDS FOR USE IN THEPREVENTION OF LEUCOCYTE ACTIVATION' | Dompé S.p.A. (IT) | 2001-10-25 | — | — | WO | claimed |
| WO-2001058852-A2 | (R)-2-ARYL-PROPIONAMIDES, USEFUL IN THE INHIBITION OF IL-8-INDUCED CHEMIOTAXIS OF NEUTROPHILS | Dompé S.p.A. (IT) | 2001-08-16 | — | — | WO | claimed |
| EP-1117677-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | Statens Serum Institut (DK) | 2001-07-25 | — | — | EP | claimed |
| WO-2000018791-A1 | LIGAND PRESENTING ASSEMBLY (LPA), METHOD OF PREPARATION AND USES THEREOF | STATENS SERUM INSTITUT (DK) | 2000-04-06 | — | — | WO | claimed |
| EP-0050799-B1 | NEW PROCESSES FOR THE PRODUCTION OF DI-ALKYL ESTERS AND OPTICALLY ACTIVE MONO-ALKYL ESTERS OF 3-AMINOGLUTARIC ACID | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1984-12-19 | — | — | EP | claimed |
| US-4415657-A | USING MICRORGANISMS FOR THE STEREOSPECIFIC HYDROGENOLYSIS OF THE DIALKYL B-PROTECTED AMINO ESTER | KANEGAFUCHI CHEMICAL INDUSTRY COMPANY, LIMITED (JP) | 1983-11-15 | — | — | US | claimed |
| EP-0050799-A1 | New processes for the production of di-alkyl esters and optically active mono-alkyl esters of 3-aminoglutaric acid | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1982-05-05 | — | — | EP | claimed |
| US-4246033-A | REACTIVE COLORLESS COMPOUND AND A COLDRED COMPOUND OR DYE | PELIKAN A.G. (CH) | 1981-01-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12378328-B2 | Biohybrid peptidoglycan oligomers | NOD2, DDOST, CD14 | SLC22A6 1316/4885GABRR1 3817/4885LMNA 1245/4885 |
| US-20250277012-A1 | CONJUGATED HEPCIDIN MIMETICS | HAMP, VIP, HDGF | SLC22A6 693/4885GABRR1 3859/4885LMNA 2431/4885 |
| US-20250360187-A1 | HEPCIDIN MIMETICS FOR TREATMENT OF SICKLE CELL DISEASE | HAMP, HBG1, HBG2 | SLC22A6 302/4885GABRR1 2683/4885LMNA 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.